Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Treasury Shares (2017 - 2025)

Arcus Biosciences (RCUS) has 8 years of Treasury Shares data on record, last reported at $2.9 million in Q4 2025.

  • For Q4 2025, Treasury Shares changed N/A year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, changed N/A, while the annual FY2025 figure was $2.9 million, N/A changed from the prior year.
  • Treasury Shares reached $2.9 million in Q4 2025 per RCUS's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.9 million in Q4 2025 and bottomed at $1.1 million in Q4 2021.
  • Average Treasury Shares over 4 years is $1.7 million, with a median of $1.4 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: soared 48.92% in 2021, then increased 15.38% in 2023.
  • A 4-year view of Treasury Shares shows it stood at $1.1 million in 2021, then increased by 18.18% to $1.3 million in 2022, then grew by 15.38% to $1.5 million in 2023, then skyrocketed by 93.33% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.9 million in Q4 2025, $1.5 million in Q4 2023, and $1.3 million in Q4 2022.